High-dose myeloablative radioimmunotherapy of mantle cell non-Hodgkin’s lymphoma with the 131I-labeled chimeric anti-CD20 antibody C2B8 and autologous stem cell support: results of a pilot study - Behr, TM; Griesinger, F; Riggert, J
Cancer, in press.